STAT‐3 contributes to pulmonary fibrosis through epithelial injury and fibroblast‐myofibroblast differentiation
Open accessThe DOI matches its Crossref record; 67 of the 68 references it cites were found in a registry or an index.
Abstract
Lung fibrosis is the hallmark of the interstitial lung diseases. Alveolar epithelial cell (AEC) injury is akey step that contributes to a profibrotic microenvironment. Fibroblasts and myofibroblasts subsequently accumulate and deposit excessive extracellular matrix. In addition to TGF‐β, the IL‐6 family of cytokines, which signal through STAT‐3, may also contribute to lung fibrosis. In the current manuscript, the extent to which STAT‐3 inhibition decreases lung fibrosis is investigated. Phosphorylated STAT‐3 was elevated in lung biopsies from patients with idiopathic pulmonary fibrosis and bleomycin (BLM)‐induced fibrotic murine lungs. C‐188‐9, a small molecule STAT‐3 inhibitor, decreased pulmonary fibrosis in the intraperitoneal BLM model as assessed by arterial oxygen saturation (control, 84.4 ± 1.3%; C‐188‐9, 94.4 ± 0.8%), histology (Ashcroft score: untreated, 5.4 ± 0.25; C‐188‐9, 3.3 ± 0.14), and attenuated fibrotic markers such as diminished α‐smooth muscle actin, reduced collagen deposition. In addition, C‐188‐9 decreased the expression of epithelial injury markers, including hypoxia‐inducible factor‐1α (HIF‐1α) and plasminogen activator inhibitor‐1 (PAI‐1). In vitro studies show that inhibition of STAT‐3 decreased IL‐6‐ and TGF‐β‐induced expression of multiple genes, including HIF‐1α and PAI‐1, in AECs. Furthermore, C‐188‐9 decreased fibroblast‐to‐myofibroblast differentiation. Finally, TGF‐β stimulation of lung fibroblasts resulted in SMAD2/SMAD3‐dependent phosphorylation of STAT‐3. These findings demonstrate that STAT‐3 contributes to the development of lung fibrosis and suggest that STAT‐3 may be a therapeutic target in pulmonary fibrosis.—Pedroza, M., Le, T. T., Lewis, K., Karmouty‐Quintana, H., To, S., George, A. T., Blackburn, M. R., Tweardy, D. J., Agarwal, S. K. STAT‐3 contributes to pulmonary fibrosis through epithelial injury and fibroblast‐myofibroblast differentiation. FASEB J. 30, 129‐140 (2016). www.fasebj.org
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Bleomycin induced pulmonary fibrosis occurs in a two-step process: 1) the immediate phase consists of an influx of macrophages and polymorphonuclear leukocytes, which release reactive oxygen species, then 2) extracellular matrix remodeling and collagen deposition [180,181].”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [181]
In the citing paper
“Both TTI-101 and S3I-201 have been tested in several mouse models of fibrosis, including bleomycin-induced lung and skin fibrosis (scleroderma) and genetically-engineered models of scleroderma, as well as a model mouse of interstitial kidney fibrosis induced by unilateral ureteral obstruction, in which inhibition of STAT3 phosphorylation by these compounds blocks the development of organ fibrosis”
From Targeting Janus Kinases and Signal Transducer and Activator of Transcription 3 To Treat Inflammation, Fibrosis, and Cancer: Rationale, Progress, and Caution (2020) · cites this paper as Pedroza et al., 2016
In the citing paper
“Importantly, in both bleomycin induced skin and lung fibrosis in mice, knockout or pharmacological inhibition of STAT3 ameliorates fibrosis (83) (81). Furthermore, in both models, STAT3 was shown to be downstream of TGFβ signaling, as inhibition of STAT3 prevented TGFβ-induced myofibroblasts formation (81, 83).”
From Unraveling SSc Pathophysiology; The Myofibroblast (2018) · cites this paper as [83]
Citations
Cites
Principles of interleukin (IL)-6-type cytokine signalling and its regulation
HEINRICH, P. C., BEHRMANN, I., HAAN, S., HERMANNS, H. M., MÜLLER-NEWEN, G., & SCHAPER, F. (2003) · Biochemical Journal · doi:10.1042/bj20030407 · Cited by 3,272
STATs: transcriptional control and biological impact
Levy, D. E., & Darnell, J. E. (2002) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm909 · Cited by 3,201 · cited 1×
“Activation of STAT-3 regulates multiple biologic functions, including cell survival, migration, proliferation, and differentiation (51).”
BackgroundInterleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway
HEINRICH, P. C., BEHRMANN, I., MÜLLER-NEWEN, G., SCHAPER, F., & GRAEVE, L. (1998) · Biochemical Journal · doi:10.1042/bj3340297 · Cited by 2,130
Simple method of estimating severity of pulmonary fibrosis on a numerical scale.
Ashcroft, T., Simpson, J. M., & Timbrell, V (1988) · Journal of Clinical Pathology · doi:10.1136/jcp.41.4.467 · Cited by 1,680 · cited 1×
“H&Estained lung sections were used to determine the Ashcroft score using 20 microscope fields per section in a blinded manner (41, 42).”
MethodInterleukin-6 family of cytokines and gp130
Kishimoto, T., Akira, S., Narazaki, M., & Taga, T. (1995) · Blood · doi:10.1182/blood.v86.4.1243.bloodjournal8641243 · Cited by 1,272
Kim, K. K., Kugler, M. C., Wolters, P. J., Robillard, L., Galvez, M. G., Brumwell, A. N., Sheppard, D., & Chapman, H. A. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0605669103 · Cited by 1,257 · cited 1×
“Current literature suggests that injury to type II AECs leads to the expression of injury markers, including HIF-1a, PAI-1, and HSP-70 (45–47, 58–60), and fibrotic markers, including Col1a1, a-SMA, TWIST, and SNAIL (4, 12, 14, 61).”
BackgroundMoeller, A., Ask, K., Warburton, D., Gauldie, J., & Kolb, M. (2008) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2007.08.011 · Cited by 1,007 · cited 1×
“The intraperitoneal model is associated with progressive subpleural pulmonary fibrosis, which resembles human pulmonary fibrosis to a greater extent than the intratracheal (40, 56, 57).”
BackgroundWillis, B. C., Liebler, J. M., Luby-Phelps, K., Nicholson, A. G., Crandall, E. D., du Bois, R. M., & Borok, Z. (2005) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)62351-6 · Cited by 951
The epidemiology of interstitial lung diseases.
Coultas, D. B., Zumwalt, R. E., Black, W. C., & Sobonya, R. E. (1994) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.150.4.7921471 · Cited by 946
Standardized Quantification of Pulmonary Fibrosis in Histological Samples
Hübner, R.-H., Gitter, W., Eddine El Mokhtari, N., Mathiak, M., Both, M., Bolte, H., Freitag-Wolf, S., & Bewig, B. (2008) · BioTechniques · doi:10.2144/000112729 · Cited by 817
TGF-β Suppresses Tumor Progression in Colon Cancer by Inhibition of IL-6 trans-Signaling
Becker, C., Fantini, M. C., Schramm, C., Lehr, H. A., Wirtz, S., Nikolaev, A., Burg, J., Strand, S., Kiesslich, R., Huber, S., et al. (2004) · Immunity · doi:10.1016/j.immuni.2004.07.020 · Cited by 726
Eitzman, D. T., McCoy, R. D., Zheng, X., Fay, W. P., Shen, T., Ginsburg, D., & Simon, R. H. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118396 · Cited by 558 · cited 1×
“2B), as well as markers of AEC injury such as HIF-1a (hypoxia-inducible factor 1a) (45), PAI-1 (plasminogen activator inhibitor-1) (46) (Fig.”
BackgroundIncidence, Prevalence, and Clinical Course of Idiopathic Pulmonary Fibrosis
Fernández Pérez, E. R., Daniels, C. E., St. Sauver, J., Hartman, T. E., Bartholmai, B. J., Yi, E. S., Ryu, J. H., & Schroeder, D. R. (2010) · Chest · doi:10.1378/chest.09-1002 · Cited by 509
Mortality from Pulmonary Fibrosis Increased in the United States from 1992 to 2003
Olson, A. L., Swigris, J. J., Lezotte, D. C., Norris, J. M., Wilson, C. G., & Brown, K. K. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200701-044oc · Cited by 435
Epithelial-Mesenchymal Interactions in Pulmonary Fibrosis
Chapman, H. A. (2011) · Annual Review of Physiology · doi:10.1146/annurev-physiol-012110-142225 · Cited by 412
Contribution of Epithelial-derived Fibroblasts to Bleomycin-induced Lung Fibrosis
Tanjore, H., Xu, X. C., Polosukhin, V. V., Degryse, A. L., Li, B., Han, W., Sherrill, T. P., Plieth, D., Neilson, E. G., Blackwell, T. S., et al. (2009) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200903-0322oc · Cited by 405 · cited 1×
“Current literature suggests that injury to type II AECs leads to the expression of injury markers, including HIF-1a, PAI-1, and HSP-70 (45–47, 58–60), and fibrotic markers, including Col1a1, a-SMA, TWIST, and SNAIL (4, 12, 14, 61).”
BackgroundKim, K. K., Wei, Y., Szekeres, C., Kugler, M. C., Wolters, P. J., Hill, M. L., Frank, J. A., Brumwell, A. N., Wheeler, S. E., Kreidberg, J. A., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci36940 · Cited by 397
Clinical deterioration in patients with idiopathic pulmonary fibrosis: Causes and assessment
Panos, R. J., Mortenson, R. L., Niccoli, S. A., & King, T. E. (1990) · The American Journal of Medicine · doi:10.1016/0002-9343(90)90495-y · Cited by 367 · cited 1×
“Key Words: fibrosis • STAT3 • epithelial injury • myofibroblast Interstitial lung diseases (ILDs), also known as diffuse parenchymal lung diseases, are a group of heterogeneous lung disorders characterized by varying degrees of inflammation and extracellular matrix (ECM) remodeling in the lung parenchyma and alveolar…”
BackgroundIsolation and primary culture of murine alveolar type II cells.
Corti, M., Brody, A. R., & Harrison, J. H. (1996) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/ajrcmb.14.4.8600933 · Cited by 319
Repetitive intratracheal bleomycin models several features of idiopathic pulmonary fibrosis
Degryse, A. L., Tanjore, H., Xu, X. C., Polosukhin, V. V., Jones, B. R., McMahon, F. B., Gleaves, L. A., Blackwell, T. S., & Lawson, W. E. (2010) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00026.2010 · Cited by 311
Jenkins, B. J., Grail, D., Nheu, T., Najdovska, M., Wang, B., Waring, P., Inglese, M., McLoughlin, R. M., Jones, S. A., Topley, N., et al. (2005) · Nature Medicine · doi:10.1038/nm1282 · Cited by 308 · cited 1×
“Alternatively, TGF-b has been shown to inhibit IL-6 trans-signaling (63) and that STAT-3 attenuates TGF-b activity in gastric adenomas (64).”
BackgroundBlockade of IL-6 Trans Signaling Attenuates Pulmonary Fibrosis
Le, T.-T. T., Karmouty-Quintana, H., Melicoff, E., Le, T.-T. T., Weng, T., Chen, N.-Y., Pedroza, M., Zhou, Y., Davies, J., Philip, K., et al. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1302470 · Cited by 299
Self-citationEstablishing Primary Adult Fibroblast Cultures From Rodents
Seluanov, A., Vaidya, A., & Gorbunova, V. (2010) · Journal of Visualized Experiments · doi:10.3791/2033 · Cited by 289 · cited 1×
“Primary type II AECs and lung fibroblasts were isolated from C57BL/6 mice as previously described (43, 44).”
MethodBleomycin-induced pulmonary fibrosis in fibrinogen-null mice
Hattori, N., Degen, J. L., Sisson, T. H., Liu, H., Moore, B. B., Pandrangi, R. G., Simon, R. H., & Drew, A. F. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10531 · Cited by 265
Stat3 Activation Links a C/EBPδ to Myostatin Pathway to Stimulate Loss of Muscle Mass
Zhang, L., Pan, J., Dong, Y., Tweardy, D. J., Dong, Y., Garibotto, G., & Mitch, W. E. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.07.012 · Cited by 263
Self-citationRedell, M. S., Ruiz, M. J., Alonzo, T. A., Gerbing, R. B., & Tweardy, D. J. (2011) · Blood · doi:10.1182/blood-2010-04-280123 · Cited by 257 · cited 1×
“C-188-9 has been used to block STAT-3 in acutemyeloid leukemia cells and musclewasting associatedwith chronic kidneydisease (38, 39).”
MethodSelf-citationLoss of SOCS3 in the liver promotes fibrosis by enhancing STAT3-mediated TGF-β1 production
Ogata, H., Chinen, T., Yoshida, T., Kinjyo, I., Takaesu, G., Shiraishi, H., Iida, M., Kobayashi, T., & Yoshimura, A. (2006) · Oncogene · doi:10.1038/sj.onc.1209281 · Cited by 246
Role of Interleukin-6 in Bleomycin-Induced Lung Inflammatory Changes in Mice
Saito, F., Tasaka, S., Inoue, K.-I., Miyamoto, K., Nakano, Y., Ogawa, Y., Yamada, W., Shiraishi, Y., Hasegawa, N., Fujishima, S., et al. (2008) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2007-0299oc · Cited by 221 · cited 1×
“systemic sclerosis (19), lungs of patients with IPF (20), and in mouse models of pulmonary fibrosis (16, 17).”
BackgroundTang, W., Geba, G. P., Zheng, T., Ray, P., Homer, R. J., Kuhn, C., Flavell, R. A., & Elias, J. A. (1996) · Journal of Clinical Investigation · doi:10.1172/jci119113 · Cited by 210 · cited 1×
“For instance, Oncostatin M is elevated in fibrotic tissues and induces pulmonary inflammation and fibrosis (53), and IL-11 is released from fibroblasts, and its overexpression induces collagen deposition in mice (54).”
BackgroundTzouvelekis, A., Harokopos, V., Paparountas, T., Oikonomou, N., Chatziioannou, A., Vilaras, G., Tsiambas, E., Karameris, A., Bouros, D., & Aidinis, V. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200705-683oc · Cited by 209
Baran, C. P., Opalek, J. M., McMaken, S., Newland, C. A., O'Brien, J. M., Hunter, M. G., Bringardner, B. D., Monick, M. M., Brigstock, D. R., Stromberg, P. C., et al. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200609-1279oc · Cited by 196 · cited 1×
“The intraperitoneal model is associated with progressive subpleural pulmonary fibrosis, which resembles human pulmonary fibrosis to a greater extent than the intratracheal (40, 56, 57).”
BackgroundLiu, Y., Liu, H., Meyer, C., Li, J., Nadalin, S., Königsrainer, A., Weng, H., Dooley, S., & ten Dijke, P. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.478685 · Cited by 181 · cited 1×
“A recent study demonstrated that TGF-b required STAT-3 activation to induce connective tissue growth factor expression during the development of liver fibrosis (62).”
BackgroundMoodley, Y. P., Scaffidi, A. K., Misso, N. L., Keerthisingam, C., McAnulty, R. J., Laurent, G. J., Mutsaers, S. E., Thompson, P. J., & Knight, D. A. (2003) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63658-9 · Cited by 165 · cited 1×
“IL-6 also has been shown to be a profibrotic cytokine inducing fibroblast proliferation and myofibroblast differentiation (27, 52).”
BackgroundSynergy between A2B Adenosine Receptors and Hypoxia in Activating Human Lung Fibroblasts
Zhong, H., Belardinelli, L., Maa, T., & Zeng, D. (2004) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2004-0103oc · Cited by 163 · cited 1×
“IL-6 also has been shown to be a profibrotic cytokine inducing fibroblast proliferation and myofibroblast differentiation (27, 52).”
BackgroundGourh, P., Arnett, F. C., Assassi, S., Tan, F. K., Huang, M., Diekman, L., Mayes, M. D., Reveille, J. D., & Agarwal, S. K. (2009) · Arthritis Research & Therapy · doi:10.1186/ar2821 · Cited by 158 · cited 1×
“systemic sclerosis (19), lungs of patients with IPF (20), and in mouse models of pulmonary fibrosis (16, 17).”
BackgroundSelf-citationMechanisms of Oncostatin M-Induced Pulmonary Inflammation and Fibrosis
Mozaffarian, A., Brewer, A. W., Trueblood, E. S., Luzina, I. G., Todd, N. W., Atamas, S. P., & Arnett, H. A. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.10.7243 · Cited by 153 · cited 1×
“For instance, Oncostatin M is elevated in fibrotic tissues and induces pulmonary inflammation and fibrosis (53), and IL-11 is released from fibroblasts, and its overexpression induces collagen deposition in mice (54).”
BackgroundO'Donoghue, R. J. J., Knight, D. A., Richards, C. D., Prêle, C. M., Lau, H. L., Jarnicki, A. G., Jones, J., Bozinovski, S., Vlahos, R., Thiem, S., et al. (2012) · EMBO Molecular Medicine · doi:10.1002/emmm.201100604 · Cited by 152 · cited 1×
“One study demonstrated that STAT-3 haploinsufficiency (STAT-3) protected mice from the development of lung fibrosis in the ITB but did investigate the ability of STAT-3 inhibition to treat fibrosis (29).”
BackgroundGene of the month: Interleukin 6 (IL-6)
Ataie-Kachoie, P., Pourgholami, M. H., Richardson, D. R., & Morris, D. L. (2014) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2014-202493 · Cited by 150 · cited 1×
“However, these cytokines do not only signal through STAT-3 but also activate other cellular pathways, such as MAPK/ERK and PI3K/Akt (32).”
BackgroundSchneider, D. J., Wu, M., Le, T. T., Cho, S., Brenner, M. B., Blackburn, M. R., & Agarwal, S. K. (2012) · The FASEB Journal · doi:10.1096/fj.11-186098 · Cited by 147 · cited 1×
“Current literature suggests that injury to type II AECs leads to the expression of injury markers, including HIF-1a, PAI-1, and HSP-70 (45–47, 58–60), and fibrotic markers, including Col1a1, a-SMA, TWIST, and SNAIL (4, 12, 14, 61).”
BackgroundSelf-citationEpithelial-Mesenchymal Interactions in Pulmonary Fibrosis
Horowitz, J., & Thannickal, V. (2006) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-2006-957332 · Cited by 146
Ueno, M., Maeno, T., Nomura, M., Aoyagi-Ikeda, K., Matsui, H., Hara, K., Tanaka, T., Iso, T., Suga, T., & Kurabayashi, M. (2011) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00146.2010 · Cited by 141
Zhou, Y., Murthy, J. N., Zeng, D., Belardinelli, L., & Blackburn, M. R. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009224 · Cited by 131 · cited 3×
“systemic sclerosis (19), lungs of patients with IPF (20), and in mouse models of pulmonary fibrosis (16, 17).”
BackgroundSelf-citationChemical Probes that Competitively and Selectively Inhibit Stat3 Activation
Xu, X., Kasembeli, M. M., Jiang, X., Tweardy, B. J., & Tweardy, D. J. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004783 · Cited by 129 · cited 2×
“C-188-9 is a synthetic small molecule STAT-3 inhibitor that targets the phospho-Tyr peptide binding pocket within the STAT-3 Src homology 2 domain (36, 55) and inhibits STAT-3 activation-receptor recruitment and homodimerization (37).”
BackgroundSelf-citationPechkovsky, D. V., Prêle, C. M., Wong, J., Hogaboam, C. M., McAnulty, R. J., Laurent, G. J., Zhang, S. S.-M., Selman, M., Mutsaers, S. E., & Knight, D. A. (2012) · The American Journal of Pathology · doi:10.1016/j.ajpath.2011.12.022 · Cited by 127 · cited 1×
“These data are consistent with prior reports that demonstrated elevated phosphoSTAT-3 in patients with IPF and also the adenosine deaminase-deficient mouse model (17, 18, 28).”
ResultRochester, C. L., Ackerman, S. J., Zheng, T., & Elias, J. A. (1996) · The Journal of Immunology · doi:10.4049/jimmunol.156.11.4449 · Cited by 121 · cited 1×
“Alternatively, it is also possible that TGF-b indirectly leads to the activation of STAT-3 by inducing IL-6 or IL-6 family members (66, 67).”
BackgroundThe burden of idiopathic pulmonary fibrosis: An unmet public health need
Lee, A. S., Mira-Avendano, I. C., Ryu, J. H., & Daniels, C. E. (2014) · Respiratory Medicine · doi:10.1016/j.rmed.2014.03.015 · Cited by 115
Pedroza, M., Schneider, D. J., Karmouty-Quintana, H., Coote, J., Shaw, S., Corrigan, R., Molina, J. G., Alcorn, J. L., Galas, D., Gelinas, R., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0022667 · Cited by 113 · cited 4×
“These data are consistent with prior reports that demonstrated elevated phosphoSTAT-3 in patients with IPF and also the adenosine deaminase-deficient mouse model (17, 18, 28).”
BackgroundResultInfluentialSelf-citationResistance to Bleomycin-Induced Lung Fibrosis in MMP-8 Deficient Mice Is Mediated by Interleukin-10
García-Prieto, E., González-López, A., Cabrera, S., Astudillo, A., Gutiérrez-Fernández, A., Fanjul-Fernandez, M., Batalla-Solís, E., Puente, X. S., Fueyo, A., López-Otín, C., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0013242 · Cited by 108 · cited 1×
“Inhibition of IL-6 trans-signaling (18) and other cytokines upstreamof STAT-3 reduces lungfibrosis in the ITB model (30, 31).”
BackgroundHeat shock protein 70 protects against bleomycin-induced pulmonary fibrosis in mice
Tanaka, K., Tanaka, Y., Namba, T., Azuma, A., & Mizushima, T. (2010) · Biochemical Pharmacology · doi:10.1016/j.bcp.2010.05.025 · Cited by 89
Elias, J. A., Lentz, V, & Cummings, P. J. (1991) · The Journal of Immunology · doi:10.4049/jimmunol.146.10.3437 · Cited by 84 · cited 1×
“Alternatively, it is also possible that TGF-b indirectly leads to the activation of STAT-3 by inducing IL-6 or IL-6 family members (66, 67).”
BackgroundMair, M., Zollner, G., Schneller, D., Musteanu, M., Fickert, P., Gumhold, J., Schuster, C., Fuchsbichler, A., Bilban, M., Tauber, S., et al. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.02.049 · Cited by 77
Pulmonary fibrosis: a cellular overreaction or a failure of communication?
Sheppard, D. (2001) · Journal of Clinical Investigation · doi:10.1172/jci13318 · Cited by 70 · cited 1×
“Injured type II AECs lead to dysregulated activation and create a profibrotic microenvironment including persistently activated wound repair pathways (7, 8).”
BackgroundDeng, P., Wang, C., Chen, L., Wang, C., Du, Y., Yan, X., Chen, M., Yang, G., & He, G. (2013) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b13-00235 · Cited by 69
STAT1/3 and ERK1/2 Synergistically Regulate Cardiac Fibrosis Induced by High Glucose
Dai, B., Cui, M., Zhu, M. J., Su, W., Qiu, M.-C., & Zhang, H. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000354499 · Cited by 69
Dave, B., Landis, M. D., Dobrolecki, L. E., Wu, M.-F., Zhang, X., Westbrook, T. F., Hilsenbeck, S. G., Liu, D., Lewis, M. T., Tweardy, D. J., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030207 · Cited by 67 · cited 1×
“C-188-9 is a synthetic small molecule STAT-3 inhibitor that targets the phospho-Tyr peptide binding pocket within the STAT-3 Src homology 2 domain (36, 55) and inhibits STAT-3 activation-receptor recruitment and homodimerization (37).”
BackgroundSelf-citationCross‐talk between IL‐6 and TGF‐β signaling in hepatoma cells
Yamamoto, T., Matsuda, T., Muraguchi, A., Miyazono, K., & Kawabata, M. (2001) · FEBS Letters · doi:10.1016/s0014-5793(01)02258-x · Cited by 66
Pulmonary Diseases and Disorders
(1989) · Annals of Internal Medicine · doi:10.7326/0003-4819-110-5-415_4 · Cited by 62
Ma, X., Chen, R., Liu, X., Xie, J., Si, K., & Duan, L. (2013) · African Journal of Traditional Complementary and Alternative Medicines · doi:10.4314/ajtcam.v10i3.10 · Cited by 60
Namba, T., Tanaka, K., Hoshino, T., Azuma, A., & Mizushima, T. (2011) · PLoS ONE · doi:10.1371/journal.pone.0027296 · Cited by 59
Dong, Z., Lu, X., Yang, Y., Zhang, T., Li, Y., Chai, Y., Lei, W., Li, C., Ai, L., & Tai, W. (2015) · BMC Pulmonary Medicine · doi:10.1186/s12890-015-0012-4 · Cited by 42 · cited 1×
“Inhibition of IL-6 trans-signaling (18) and other cytokines upstreamof STAT-3 reduces lungfibrosis in the ITB model (30, 31).”
BackgroundAlveolar Epithelium: Beyond the Barrier
Borok, Z. (2014) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2014-0089ps · Cited by 27
Arsenic trioxide prevents rat pulmonary fibrosis via miR-98 overexpression
Gao, S., Zhou, X. M., Li, Y., Liu, W., Wang, P., Pang, M., Xie, S., & Lv, C. (2014) · Life Sciences · doi:10.1016/j.lfs.2014.07.037 · Cited by 27
Shigekawa, M., Takehara, T., Kodama, T., Hikita, H., Shimizu, S., Li, W., Miyagi, T., Hosui, A., Tatsumi, T., Ishida, H., et al. (2011) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2011.02.105 · Cited by 22
Xu, C., Li, X., Hu, Y., Cui, Z., Wang, L., Liang, L., Zhou, Y.-L., Yang, Y., & Yu, B. (2014) · Journal of Proteomics · doi:10.1016/j.jprot.2014.11.002 · Cited by 21
SH2 domain binding to phosphopeptide ligands: potential for drug targeting
Moses, M. K. (2009) · Frontiers in bioscience · doi:10.2741/3292 · Cited by 18 · cited 1×
“C-188-9 is a synthetic small molecule STAT-3 inhibitor that targets the phospho-Tyr peptide binding pocket within the STAT-3 Src homology 2 domain (36, 55) and inhibits STAT-3 activation-receptor recruitment and homodimerization (37).”
BackgroundPinart, M., Serrano‐Mollar, A., Llatjós, R., Rocco, P. R. M., & Romero, P. V. (2009) · Respiratory Physiology & Neurobiology · doi:10.1016/j.resp.2009.01.002 · Cited by 18 · cited 2×
“035U/g BLMor PBS (control) via the intraperitoneal route twice per week for 4 wk (40).”
BackgroundMethodSulindac has strong antifibrotic effects by suppressing STAT 3‐related miR‐21
Zhou, X. M., Li, Y., Gao, S., Wang, X., Wang, P., Yan, Y., Xie, S., & Lv, C. (2015) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.12506 · Cited by 18
Cited by
Nieto, M. A., Huang, R. Y.-J., Jackson, R. A., & Thiery, J. P. (2016) · Cell · doi:10.1016/j.cell.2016.06.028 · Cited by 4,492
Bharadwaj, U., Kasembeli, M. M., Robinson, P., & Tweardy, D. J. (2020) · Pharmacological Reviews · doi:10.1124/pr.119.018440 · Cited by 314
“…in which inhibition of STAT3 phosphorylation by these compounds blocks the development of organ fibrosis by reducing expression levels of proteins that mediate fibrosis and impairing myofibroblast differentiation (Pang et al., 2010; Pedroza et al., 2016, 2017; Chakraborty et al., 2017).”
BackgroundSelf-citationRole of JAK/STAT in Interstitial Lung Diseases; Molecular and Cellular Mechanisms
Montero, P., Milara, J., Roger, I., & Cortijo, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126211 · Cited by 254
“Further, STAT3 regulates IL-6–mediated and TGF-β1–mediated myofibroblast differentiation in murine lung fibroblasts [30], and inhibition of STAT3 was found to reduce TGFβ1-induced FMT in fibroblasts, and ameliorate skin fibrosis in two mouse models of systemic sclerosis [82].”
BackgroundInfluentialCellular senescence: Molecular mechanisms and pathogenicity
Wei, W., & Ji, S. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.26956 · Cited by 210
“Inhibition of STAT3 reduces the expression of IL‐6 and TGF‐β‐regulated gene expression, and decreases fibroblast‐ to‐myofibroblast differentiation (Pedroza et al., 2015).”
BackgroundKasembeli, M. M., Bharadwaj, U., Robinson, P., & Tweardy, D. J. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19082299 · Cited by 199
“Additionally, myofibroblast differentiation was mitigated [63].”
BackgroundSelf-citation
Metadata
- Authors
- Pedroza, M., Le, T. T., Lewis, K., Karmouty‐Quintana, H., To, S., George, A. T., Blackburn, M. R., Tweardy, D. J., & Agarwal, S. K.
- Affiliations
- Baylor College of Medicine (US)
- The University of Texas Health Science Center at Houston (US)
- Corresponding author
- Agarwal, Sandeep K.
- ORCID
- Venue
- The FASEB Journal
- Publisher
- Wiley
- Published
- 2015-08-31
- Volume
- 30
- Issue
- 1
- Pages
- 129-140
- ISSN
- 0892-6638 (ISSN-L)
- 1530-6860
- PMC
- PMC4684532
- OpenAlex
- W1853941740
- Cited by
- 193
- References
- 68
- Citations by year
- 2026: 13 · 2025: 20 · 2024: 24 · 2023: 25 · 2022: 27 · 2021: 20 · 2020: 15 · 2019: 14 · 2018: 17 · 2017: 10 · 2016: 7 · 2015: 1
- FWCI
- 9.24
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- The FASEB Journal (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- U.S. Department of Defense
- National Institutes of Health (R01AR062056, K08AR054404, 2T32AI053831‐11A1)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Surgery › Transplantation: Methods and Outcomes
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Keywords
- STAT3, pulmonary fibrosis, idiopathic pulmonary fibrosis, alveolar epithelial cell injury, myofibroblast differentiation, bleomycin-induced lung fibrosis, IL-6 signaling, TGF-beta signaling, HIF-1α, plasminogen activator inhibitor-1, extracellular matrix deposition, therapeutic target
- MeSH terms
- Animals, Bleomycin, Cell Differentiation, Disease Models, Animal, Epithelial Cells, Lung, Male, Mice, Inbred C57BL, STAT3 Transcription Factor, Idiopathic Pulmonary Fibrosis, Myofibroblasts
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.